Uppsala, Sweden, February 20, 2017. Biovica has strengthened its management team to ensure continued successful development. Cecilia Driving (CFO), Karin Mattsson (R&D Director) and Johanna Faris (Quality and Regulatory Assurance Director) have joined the company.
Cecilia Driving holds a dual degree in BA and law. She has held several CFO positions in life science, private equity, research and telecom companies. Her previous experience includes IPO processes and working in publicly-listed companies. Cecilia is also a board member of Acreo Swedish ICT AB.
Karin Mattsson holds a PhD in Cell- and Tumor Biology from the Karolinska Institutet. She has over 20 years’ industrial experience, including roles as product manager and R&D Director at Olerup SSP, a company that develops, manufactures and markets in vitro diagnostic products in Europe and the United States. Karin has successfully contributed to the development and commercialization of these products.
Johanna Faris has extensive experience of ISO 13485 and QSR quality standards, as well as worldwide product registration. In her most recent role as Quality and Regulatory Director at Fiomi Diagnostics AB, she led the implementation of a certified quality management system and regulatory processes in both Europe and the United States.
“These key recruitments strengthen our management team, secure important positions for the upcoming company IPO, and lay the foundation for a successful market introduction of our DiviTum™ biomarker assay. DiviTum™ addresses a large unmet diagnostic need. Biovica will be able to provide great value for both patients and payers”, – Anders Rylander, CEO Biovica.